RECRUITING

A Study of Revaree Plus in People With Breast Cancer

Description

The purpose of this study is to find out whether Revaree Plus is effective at improving vaginal health for people who are having symptoms of vaginal dryness during breast cancer treatment.

Conditions

Breast CancerStage 0 Breast CancerStage I Breast CancerStage II Breast CancerStage III Breast CancerStage 0 Breast CarcinomaStage II Breast CarcinomaStage III Breast CarcinomaHormone-receptor-positive Breast CancerHormone Receptor Positive Breast CarcinomaHormone Receptor Positive Malignant Neoplasm of Breast
Talk to us

Related Conditions:

Breast CancerStage 0 Breast CancerStage I Breast CancerStage II Breast CancerStage III Breast CancerStage 0 Breast CarcinomaStage II Breast CarcinomaStage III Breast CarcinomaHormone-receptor-positive Breast CancerHormone Receptor Positive Breast CarcinomaHormone Receptor Positive Malignant Neoplasm of Breast

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to find out whether Revaree Plus is effective at improving vaginal health for people who are having symptoms of vaginal dryness during breast cancer treatment.

Evaluation of Revaree Plus in Women With Breast Cancer

A Study of Revaree Plus in People With Breast Cancer

Condition
Breast Cancer
Intervention / Treatment

-

Contacts and Locations

Basking Ridge

Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey, United States, 07920

Middletown

Memorial Sloan Kettering Monmouth (Consent Only), Middletown, New Jersey, United States, 07748

Montvale

Memorial Sloan Kettering Bergen (Consent Only), Montvale, New Jersey, United States, 07645

Commack

Memorial Sloan Kettering Cancer Center Suffolk-Commack (Consent Only), Commack, New York, United States, 11725

Harrison

Memorial Sloan Kettering Westchester (Consent Only), Harrison, New York, United States, 10604

New York

Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10021

Uniondale

Memorial Sloan Kettering Nassau (Consent Only), Uniondale, New York, United States, 11553

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * ≥18 years of age at the time of signing informed consent.
  • * Stage 0-3 hormone-receptor positive breast cancer confirmed at MSKCC
  • * Able to complete study questionnaires in English or Spanish
  • * Breast cancer patients must have completed chemotherapy or radiation therapy (and can be on maintenance therapy)
  • * Currently on an aromatase inhibitor or tamoxifen
  • * Currently have no clinical evidence of disease
  • * Reporting being bothered by vaginal symptoms of estrogen deprivation (i.e., vaginal dryness, dyspareunia, or discomfort \[pain with intercourse or examination\])
  • * A total score of 4 or greater in VAS
  • * Without history of other cancers (excluding non-melanoma skin cancer)
  • * Must sign an informed consent indicating that the participant understands the purpose of, and procedures required for the study and is willing to participate in the study
  • * Inability to provide informed consent
  • * Vaginal bleeding of unknown etiology within 12 months of study entry
  • * Currently taking hormone replacement therapy \[local or systemic\] (Patients must discontinue for 4 weeks in order to be eligible prior to study enrollment)
  • * Existing use of external estrogens or nonhormonal moisturizers (Patients must discontinue for 4 weeks in order to be eligible prior to study enrollment)
  • * No known allergies to any ingredients in 10mg HLA suppository

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Memorial Sloan Kettering Cancer Center,

Shari Goldfarb, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

2029-06-20